The Lancet Psychiatry The Lancet Psychiatry – Volume 12 – Issue 5 – May 2025
Editorial
Setting the research agenda for mental health
The Lancet Psychiatry
Comment
Brexpiprazole for the treatment of adolescent schizophrenia
Maria Rogdaki
Cardiovascular effects of ADHD medications
Steven R Pliszka
Priovi appears to be a valuable digital tool for patients with borderline personality disorder
Vivian B Pender
Time to report estimands in randomised controlled trials
Erica Neill,
Ravi Iyer,
Philip Sumner,
Andrew Mackinnon
India’s need for a national dementia policy
Anupa Anirudhan,
Hansel Chris Rodrigues,
Thomas Gregor Issac
India’s mental health budget 2025 needs urgent reform
Sheikh Shoib,
Ilham Zaidi,
Miyuru Chandradasa,
Sujita Kumar Kar,
Fahimeh Saeed
Correspondence
Accurate prevalence estimates needed for youth common mental disorders
Patrick D McGorry,
Eóin Killackey,
Eric Chen,
Andrew Chanen
Accurate prevalence estimates needed for youth common mental disorders – Authors‘ reply
Ellie M Robson,
Susan M Sawyer
on behalf of the Article coauthors
Does ADHD treatment inefficacy question its diagnostic validity?
Gin S Malhi,
Kinga Szymaniak,
Erica Bell
Does ADHD treatment inefficacy question its diagnostic validity? – Authors‘ reply
Edoardo G Ostinelli,
Andrea Cipriani,
Samuele Cortese
Bipolar depression management needs randomised controlled trial evidence
Chien Cheng,
Tien-Wei Hsu,
Yu-Chen Kao,
Mu-Hong Chen,
Chih-Sung Liang
Bipolar depression management needs randomised controlled trial evidence – Authors‘ reply
Cagatay Ermis,
Heidi Taipale,
Jari Tiihonen
on behalf of all authors of the Article
Articles
Cost-effectiveness of a group psychological intervention for postnatal depression in British south Asian women: an economic evaluation from the ROSHNI-2 trial
Akbar Ullah,
Farah Lunat,
Traolach Brugha,
Matthias Pierce,
Richard Morriss,
Deepali Sharma,
Atif Rahman,
Kamaldeep Bhui,
Peter Bower,
Nusrat Husain
Efficacy and safety of brexpiprazole in adolescents with schizophrenia: a multicountry, randomised, double-blind, placebo-controlled, phase 3 trial with an active reference
Caroline Ward,
Milica Pejović Milovančević,
Eva Kohegyi,
Nanco Hefting,
Catherine Aurang,
Dalei Chen,
Klaus Groes Larsen,
Mary Hobart,
Christoph U Correll
Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis
Luis C Farhat,
Alice Lannes,
Cinzia Del Giovane,
Valeria Parlatini,
Miguel Garcia-Argibay,
Edoardo G Ostinelli,
Anneka Tomlinson,
Zheng Chang,
Henrik Larsson,
Cristiano Fava,
François Montastruc,
Andrea Cipriani,
Alexis Revet,
Samuele Cortese
A digital therapeutic for people with borderline personality disorder in Germany (EPADIP-BPD): a pragmatic, assessor-blind, parallel-group, randomised controlled trial
Nele Assmann,
Gitta Jacob,
Anja Schaich,
Thomas Berger,
Tristan Zindler,
Linda Betz,
Stefan Borgwardt,
Arnoud Arntz,
Eva Fassbinder,
Jan Philipp Klein
Review
Factors that affect the resilience of young adults to depression: a systematic review
Linda Theron,
Dov J Stekel,
Jan Höltge,
Olufunmilayo I Fawole,
Diane T Levine,
Zainab Mai-Bornu,
Kassa Maksudi,
Olanrewaju Olaniyan,
Caradee Y Wright,
Michael Ungar
Health Policy
INTEGRATE: international guidelines for the algorithmic treatment of schizophrenia
Robert A McCutcheon,
Toby Pillinger,
Ioana Varvari,
Sean Halstead,
Olatunde O Ayinde,
Nicolás A Crossley,
Christoph U Correll,
Margaret Hahn,
Oliver D Howes,
John M Kane,
Thomas Kabir,
Åsa Konradsson-Geuken,
Belinda Lennox,
Christy Lai Ming Hui,
Susan L Rossell,
Marco Solmi,
Iris E Sommer,
Heidi Taipale,
Hiroyuki Uchida,
Ganesan Venkatasubramanian,
Nicola Warren,
The INTEGRATE Advisory Group,
Dan Siskind